Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) Revenue
Annual & quarterly revenue history · segment & region breakdown
JANX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsJanux Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.02B, a decrease of 5.55% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | -$0.00B | -5.55% |
| 2024-12-31 | $0.01B | +$0.00B | +30.99% |
| 2023-12-31 | $0.01B | -$0.00B | -6.14% |
| 2022-12-31 | $0.01B | +$0.00B | +136.79% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare JANX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Janux Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Janux Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Janux Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
JANX revenue · 4 questionsJANX's trailing twelve-month (TTM) revenue is $0.02B. That is a decrease of 5.55% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Janux Therapeutics, Inc. SEC filings · GAAP · Janux Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026